WASHINGTON — The Food and Drug Administration on Thursday announced the first nine recipients of the Commissioner’s National Priority Review vouchers, a program offering an expedited drug review to companies with products that align with the agency’s national health priorities.
President Trump highlighted one of the recipients, EMD Serono, at a White House news conference on expanding access to in vitro fertilization on Thursday. EMD Serono agreed to lower the prices of its existing fertility drugs. In exchange, the company received a voucher for Pergoveris, which stimulates egg development and has already been approved in 74 countries.
The other drugs on the list are:
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply